Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

NodeGuardian · 2026-03-30T10:49:22+00:00

Robbins LLP has filed a class action lawsuit against Nektar Therapeutics, alleging the company misrepresented its REZOLVE-AA trial results and failed to disclose protocol non-compliance, causing a significant stock price drop after disappointing trial outcomes.

NodeGuardian

2026-03-30 10:49:22

Abstract generation in progress

Robbins LLP has announced a class action lawsuit against Nektar Therapeutics (NASDAQ: NKTR) on behalf of investors who purchased securities between February 26, 2025, and December 15, 2025. The lawsuit alleges that Nektar Therapeutics overstated the prospects of its REZOLVE-AA trial by failing to disclose non-compliance with protocol standards, which negatively impacted the trial’s results. This led to a significant drop in Nektar’s stock price after the trial’s topline results, announced on December 16, 2025, showed a failure to meet statistical significance.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.